Compare the paths before choosing one
These are categories, not a ranked treatment ladder. Compare only the paths that are realistic for you with a clinician.
Wait or choose no active treatment
When treatment is not wanted now, or its burden outweighs the goal.
Avoids treatment burden while leaving room to revisit the decision.
Does not aim to restore pigment or stop change.
Low treatment burden; still agree on skin protection, support, and review.
Usually does not depend on treatment coverage.
The choice is reversible, but vitiligo may change while you wait.
Camouflage and supportive care
When the immediate goal is appearance, confidence, or day-to-day support.
Can change appearance immediately and support wellbeing.
Does not treat pigment loss; products can irritate or transfer.
Application, removal, product matching, and cost vary.
Cosmetic and support resources vary and may be self-paid.
Usually reversible; product fit is individual.
Prescription creams or ointments
When a clinician thinks a topical option matches the diagnosis, body area, and goal.
Some options improve repigmentation for some people studied.
Products have different labels, evidence, precautions, and risks.
Regular application and follow-up can be substantial.
Prescription coverage and authorization vary.
Treatment can be stopped with clinical guidance; personal response is uncertain.
Clinician-directed light treatment
When phototherapy is clinically appropriate and repeated visits or home treatment are workable.
Can support repigmentation for some patterns and body areas.
Response varies and qualified oversight and precautions remain necessary.
Repeated sessions, travel or home-device routines, and follow-up.
Clinic capacity, device coverage, and supplier rules can limit access.
Sessions can be paused by the care team; result and durability vary.
Whole-body or research medicines
Only in selected clinical situations or a properly governed study.
May target broader disease activity or answer an unmet need.
Status, evidence, monitoring, and material risks differ by exact medicine.
Clinical monitoring and uncertainty may be higher.
Approval, specialist care, trials, and coverage differ.
Stopping does not erase every risk; early evidence may change.
Specialist procedures
For carefully selected stable vitiligo in experienced settings.
May restore pigment in selected patches.
Healing, incomplete or uneven results, and procedure risks matter.
Assessment, procedure, recovery, and follow-up.
Specialist availability and coverage can be limited.
A procedure is less reversible; color match and durability are uncertain.
Do I have to start treatment now?
No. Once your diagnosis and any related health questions are settled, choosing no active treatment can be a deliberate option, not a failure to act. You can revisit the decision if your skin, health, or priorities change. Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
The patient and clinical guidance I read treats treatment as optional and says goals differ. You can still protect your skin and get emotional support while you wait. You can also agree on which changes to track.
Considerations
- Depends on you
Vitiligo may still change while you wait. Agree with your clinician on when to review it and which changes should bring you back sooner.
Questions for your clinician
What should I track if I wait?
Saving keeps this on your device and needs JavaScript, which is off in this browser.When should I contact you?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What support is available if I do not want treatment now?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What if my main goal is how my skin looks right now?
You can use camouflage, cosmetics, self-tanning products, or clothing if you want an immediate, reversible change in appearance. You can also choose not to conceal your skin. These choices do not treat the underlying pigment loss, but they can still matter to how you want to move through daily life. Evidence Evidence
Why this matters
- Sources cited, not yet graded
The guidelines I read include camouflage among legitimate management choices and recognize the emotional and social effects of vitiligo. You can use appearance options alone, alongside clinician-directed care, only in certain situations, or not at all.
Considerations
- Depends on you
Products vary in ingredients, finish, transfer, skin sensitivity, cost, and suitability for a particular area. Covering a patch does not tell you whether vitiligo is changing.
Questions for your clinician
Where can I get help with camouflage?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Should I remove camouflage before an exam or clinical photo?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What are the prescription creams and ointments I may hear about?
Vitiligo creams include corticosteroids, Protopic (tacrolimus), Elidel (pimecrolimus), and Opzelura (ruxolitinib). These are not different brands of one cream. Each has its own approval status, evidence, risks, best body areas, follow-up needs, availability, and cost. Evidence Evidence Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
The current guidelines I read discuss several creams. I checked the US labels. Ruxolitinib is approved for a defined group with vitiligo. Tacrolimus, pimecrolimus, and topical corticosteroids do not have that specific US approval.
Considerations
- Depends on you
Evidence for one product cannot be transferred to another, and an average study result cannot predict what will happen to your patches. The exact prescription and current label matter, and availability or insurance rules can change.
Questions for your clinician
Is this medicine approved for vitiligo here or used off-label?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What benefits and risks apply to this exact medicine?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
When might light treatment come up?
Narrowband UVB and targeted light are established clinician-directed options for some people with vitiligo. Treatment in a clinic and treatment at home create different practical burdens, but neither setting guarantees repigmentation or removes the need for qualified oversight. Evidence Evidence
Why this matters
- Sources cited, not yet graded
The guidelines I read discuss narrowband UVB across vitiligo patterns and body areas, and targeted devices for more localized patches. Group results show that response can differ by body site and that not everyone repigments.
Considerations
- Depends on you
Whether light treatment fits depends on your pattern, goals, medicines, access, and eye and skin precautions. A qualified team must choose the device and provide operating instructions.
Questions for your clinician
Why might light treatment fit my pattern and goal?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What would clinic treatment and home treatment each require from me?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What should I track, and how will we judge whether it is helping?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Three more answers: pills and research medicines, when a procedure might be considered, and how to decide which options are worth discussing
Could pills or research treatments be options for me?
They may come up in selected clinical situations, and newer immune-targeting medicines are being studied. But “promising,” “used by some specialists,” and “approved for vitiligo” mean different things. A research result or approval for another condition does not make a medicine established for your vitiligo. Evidence Evidence
Why this matters
- Sources cited, not yet graded
The international guidance I read discusses medicines that work throughout the body for selected goals. Clinical trials continue to investigate other medicines and combinations. Check the status, evidence, health restrictions, monitoring, and access for the exact medicine where you live.
Considerations
- Depends on you
This area changes quickly, and early findings may not apply to you. A biological mechanism does not establish suitability or support unapproved access.
Questions for your clinician
Is this established care, off-label use, or a research study?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What key risks, unknowns, and alternatives should I understand?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
When might a procedure be considered?
Procedures that move or prepare pigment-producing cells are specialist options for carefully selected people with stable vitiligo. They are not an automatic next step after creams or light treatment. You also need to consider eligibility, risks, healing, access, and incomplete or uneven results. Evidence Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
The consensus and guideline sources I read reserve surgery for selected stable vitiligo in experienced settings. I checked the US authorization for RECELL. It covers color return in stable white vitiligo patches in adults under defined conditions. It does not approve every procedure or every person.
Considerations
- Depends on you
“Stable” is a clinical judgment, and a procedure cannot guarantee color match, permanence, or satisfaction. Your body site, history, clinician’s experience, coverage, and local availability all affect whether a procedure is realistic.
Questions for your clinician
How do you know my vitiligo is stable enough for this?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What benefits and harms are reported for this procedure here?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What happens if healing or repigmentation misses the goal?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
How do I decide which options are worth discussing for me?
People I have heard from get stuck here more than anywhere else. Start with the goal you want help with. Then compare your realistic options using the same questions. Evidence Evidence Evidence
- Who was studied?
- What result is possible?
- What is still unknown?
- What are the risks and day-to-day effort?
- What follow-up and access does it need?
- What would choosing no active treatment mean?
Why this matters
- Sources cited, not yet graded
The guidelines I read support shared decisions that account for the characteristics of vitiligo and its effect on your life. They present multiple paths rather than one treatment ladder everyone must climb.
Considerations
- Depends on you
A comparison table cannot calculate the right answer for you, and missing evidence should not become a made-up score. It is reasonable for your choice to change if your goals, health, access, or the evidence changes.
Questions for your clinician
Which options are realistic for my type of vitiligo and my goal?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Can we compare the same benefits, risks, burden, and unknowns?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What if the burden or cost outweighs the likely benefit?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Questions that can change the next decision
For your clinicianGiven my diagnosis, activity, body areas, health history, and goal, which paths are realistic to compare?
Saving keeps this on your device and needs JavaScript, which is off in this browser.For your clinicianHow do the realistic paths differ in possible benefit, material harms, burden, access, and uncertainty?
Saving keeps this on your device and needs JavaScript, which is off in this browser.For your clinicianWhat would make us review, pause, or change the plan?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
Narrowband UVB and targeted light are established clinician-directed options for some people with vitiligo. Treatment in a clinic and treatment at home create different practical burdens, but neither setting guarantees repigmentation or removes the need for qualified oversight.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a group-level outcome claim, but exact population extraction is still pending. It cannot publish or support an individual prediction until that review is complete.
Procedures that move or prepare pigment-producing cells are specialist options for carefully selected people with stable vitiligo. They are not an automatic next step after creams or light treatment. You also need to consider eligibility, risks, healing, access, and incomplete or uneven results.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a safety claim, but exact population extraction is still pending. It cannot publish or support an estimate of individual risk until that review is complete.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
Protopic (tacrolimus) ointment: US prescribing information and Medication Guide (opens in a new tab)
DailyMed, U.S. National Library of MedicineRegulatory · Regulatory / guideline, tier 1Relevant relationship disclosed- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
It establishes the US atopic-dermatitis indication, boxed warning, local effects, long-term-use precaution, and ultraviolet instructions for this product. Its mechanism-of-action section supports that tacrolimus binds FKBP-12 to block calcineurin phosphatase, preventing the T-cell activation that its boxed warning and local-effect data describe. Its local-adverse-reaction data supports burning in roughly 46-58% and itching in roughly 41-46% of studied patients, most often in the first few days and easing as treatment continues. Its Dosage and Administration section supports applying a thin layer twice daily and re-examining the patient if signs and symptoms do not improve within six weeks.
What it does not support
It does not approve tacrolimus for vitiligo or psoriasis, establish efficacy for either, or resolve off-label guideline discussion of supervised combinations. Its dosing and six-week re-examination window are stated for its approved atopic-dermatitis indication, not as a vitiligo-specific schedule.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- DailyMed, U.S. National Library of MedicineRegulatory · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
Supports the US atopic-dermatitis indication, boxed warning, application-site effects, long-term-use precaution and instructions to avoid ultraviolet treatment and minimize natural or artificial sunlight. This label itself is a generic pimecrolimus cream filing (packager Oceanside Pharmaceuticals, a division of Bausch Health US, LLC), not the original brand Elidel label, so it also supports that a generic pimecrolimus cream is currently marketed. Its Dosage and Administration section supports applying a thin layer twice daily and re-examining the patient if signs and symptoms persist beyond six weeks; its boxed warning separately supports that continuous long-term use should be avoided. Its adult 1-year active-comparator adverse-reaction table (328 pimecrolimus-treated subjects) supports application-site burning in about 25.9%, headache in about 25.4%, nasopharyngitis in about 7.6%, and influenza in about 9.8% of that adult trial population.
What it does not support
It does not approve pimecrolimus for vitiligo or psoriasis, establish efficacy for either, or resolve off-label guideline discussion of supervised combinations. Its dosing and six-week re-examination window, and its adult adverse-reaction percentages, are stated for its approved atopic-dermatitis indication and trial population, not as a vitiligo-specific schedule or vitiligo-trial safety rate.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- DailyMed, U.S. National Library of MedicineRegulatory · Regulatory / guideline, tier 1Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the defined US nonsegmental-vitiligo indication, limitations of use, boxed warnings, skin-cancer and ultraviolet precautions, and clinical-study labeling.
What it does not support
It also supports the labeled dosing instruction: "Apply a thin layer of OPZELURA topically twice daily to affected areas of up to 10% body surface area." It further supports the labeled re-evaluation point: "If the patient does not find the repigmentation meaningful by 24 weeks, the patient should be re-evaluated by the healthcare provider." It also supports the vitiligo-trial adverse-reaction rates at 1% incidence or greater: application-site acne 6%, application-site itching 5%, a common-cold-type illness (nasopharyngitis) 4%, headache 4%, urinary tract infection 2%, application-site redness (erythema) 2%, and fever (pyrexia) 1%. It does not guarantee benefit, establish suitability beyond the labeled population, authorize adding phototherapy, or state which reaction should prompt a call to the prescriber beyond directing patients to the Medication Guide and their healthcare provider.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports FDA authorization of this device for repigmentation of stable depigmented vitiligo lesions in a defined adult population and trained professional setting.
What it does not support
It does not approve every grafting procedure, define stability for a reader or guarantee color match, durability or satisfaction.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- JAMA Dermatology (Ju HJ, et al.)Systematic review · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that multiple surgical techniques have been studied for selected stable vitiligo and that reported response and adverse effects vary by method and study.
What it does not support
Much of the evidence is nonrandomized and an author reported industry relationships; the review does not determine stability, eligibility, color match, durability or individual outcome.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making. Its modified assessment check list names where the patches are as a disease feature, and gives genital involvement as its own example. It records white hairs as an item of its own, apart from what the vitiligo has done in the past six months. Its classification table keeps mucosal vitiligo as a subtype, both across more than one site and at one site alone. It supports planning care around what is there to work with, and its example is hair that still has its color. It names stable vitiligo and active vitiligo as two different states that change the care plan. Its shared-decision steps ask what the patient wants from care. At the time it was written, one cream form of a newer drug type had just been approved. Pill forms of that same drug type were still being studied.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph. It gives no figure for genital involvement, and it does not name lichen sclerosus. It does not set out the Vitiligo European Task Force grading scale. It puts no figure on white hairs and predicts nothing for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition. R28 offers a skin camouflage visit to people who want one. R10 to R14 name potent or very potent topical steroids as the first choice, with a topical calcineurin-inhibitor cream as an option for the face. These are different creams with different proof behind them. R20 names narrowband UVB as the first light option. It says the skin often does better on the face and trunk than on hands and feet. It says there is not enough proof to use any one current pill alone for vitiligo that is not changing. R25 and Table 2 keep cell grafting for vitiligo that is not changing and did not respond to other care. They also say a doctor cannot always tell if the vitiligo has truly stopped changing.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a patient-facing description of clinician diagnosis using history and examination, possible use of a Wood lamp and selected tests, broad treatment categories, variable response and whole-person support.
What it does not support
It is educational context, not primary efficacy evidence, an online diagnostic method or a universal testing checklist.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports current US patient-language context that lighter patches have multiple causes, dermatologists diagnose vitiligo from history and examination, treatment is optional and several broad management paths exist.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish drug efficacy or comparative superiority.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.